MARKSANS PHARMA
Q1 FY 18-19 REVIEW
CONSOLIDATED REVENUE OF RS.238 CR IN Q1 (221.09 CR), A
GROWTH OF 7.87%
EBITDA WAS
RS.38.72 CR (29.03 CR), A GROWTH OF 33.38%
CONSOLIDATED EBIDA WAS 16.23% OF REVENUE
PBT WAS 30.36 CR
PAT AT 25.14 CR (13.64 CR), A GROWTH OF 84.31%
q.EPS stands at 0.58 on FV of Rs.1and on this
annualized PE ratio is 15
Maximum exports are to Europe and north America incl
USA
Marksans Pharma Limited is engaged in Research, Manufacturing
& Marketing of generic pharmaceutical formulation in the global markets.
The company's manufacturing facilities are approved by several leading regulatory agencies
including USFDA, UKMHRA and Australian TGA.
The company's robust product portfolio spreads over major
therapeutic segments of CVS, CNS, Anti-diabetic,
Pain Management, Gastroenterologicals and Anti-allergies.
The company is marketing these products globally.
|
MP
|
35
|
||||||
|
PE
|
15
|
||||||
|
VOLUME
|
2002748
|
||||||
|
FV
|
1
|
||||||
|
PRICE TREND
|
|||||||
|
14.08.18
|
1 week
|
2 week
|
1 month
|
3 month
|
6 month
|
9 month
|
1 year
|
|
Price
|
32.55
|
28.1
|
26.05
|
27.45
|
40.85
|
41.85
|
40.45
|
|
Gain / Loss
|
-5.99%
|
8.90%
|
17.47%
|
11.48%
|
-25.09%
|
-26.88%
|
-24.35%
|
No comments:
Post a Comment